Form 4: Beam Therapeutics Director, John Maraganore, Reports Stock Option Grant

Director John Maraganore reports receiving a stock option grant from Beam Therapeutics.

Summary

• John Maraganore, a director of Beam Therapeutics Inc., filed a Form 4 on June 7, 2024, reporting a transaction that occurred on June 5, 2024.
• The transaction involved the acquisition of a stock option (right to buy) 23,114 shares of Beam Therapeutics common stock at an exercise price of $24.49.
• The option vests in full on the earlier of the first anniversary of the grant date or immediately prior to the date of the next year's annual meeting of stockholders, contingent upon continued service on the board.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard stock option grant to a director, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in the biotechnology industry.
• The vesting schedule is typical, incentivizing long-term commitment to the company's success.
• Comparable companies such as CRISPR Therapeutics and Editas Medicine also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates